MEASLES Case and Outbreak 'Quicksheet'

To be used as a checklist for determining potential measles cases and assisting in the completion of the Measles Case Report, form DHS # 8345.

Infectious agent: The measles virus is a paramyxovirus, genus Morbillivirus

Mode of transmission: a) Person to person - via large respiratory droplets (most common) or b) Airborne via aerosolized droplet nuclei (tiny droplets suspended in the air for up to 2 hours)

CDC CASE DEFINITION and CLASSIFICATION (for purposes of public health reporting)

Clinical Case Definit	ion: A generalized maculopapular rash of at least 3 days duration, AND a fever				
equal to or greater than 101 degrees Fahrenheit (orally), AND one or more of the following: \square cough,					
□ coryza, or □ conjunctivitis.					
•					
Case Classification:	Confirmed - \square meets <u>clinical case definition</u> , and \square is serologically confirmed or				
	epidemiologically linked to another confirmed case.				
	Probable - meets clinical case definition				
	Suspected - any rash illness with fever				
	1				

CLINICAL FEATURES

Incubation

Exposure to prodrome: average 10-12 days

Exposure to onset of rash: average 14 days (maximum range 7-18 days)

Prodrome

Begins 10-12 days after exposure to virus; generally lasts 2-4 days, with a maximum range of 1-7 days Fever and malaise for about 24 hours; fever gradually increases often as high as 103-105 degrees F Cough, coryza (runny nose), and conjunctivitis

Koplik's spots may occur 1-2 days before rash to 1-2 days after rash. They appear as pin-point, depressed bluewhite spots on bright red background on the buccal mucosa.

Rash

Maculopapular, usually lasting 5-6 days

Begins at the hairline, then involves the face and upper neck

During the next three days, gradually proceeds downward and outward, reaching extremities last and being less pronounced on hands and feet.

Usually becomes confluent on face and chest

Rash fades in the same order that it appears, from head to feet

LABORATORY TESTING AND CONFIRMATION

☐ Significant IgM measles antibody in serum collected 2-28 days after rash onset
☐ Significant rise in measles IgG in paired and acute convalescent sera drawn two weeks apart
☐ Virus isolation by urine or nasopharyngeal specimen, collected before fifth day of rash onset, to be used as
an epidemiologic tool for DNA genotyping

RECOMMENDED TREATMENT AND CHEMOPROPHYLAXIS

Treatment	Children	Adults
Immune Globulin (IG)	Give within six days of exposure to infants less than 1 year old w/o previous measles vaccine. Dose is 0.25 mL/kg of body weight (.5 mL/kg for immunocompromised children) with a maximum dose of 15 mL.	Appropriate for known or presumed susceptible pregnant women or immunocompromised persons. Dose is 0.25 mL/kg of body weight (.5 mL/kg for immunocompromised children) with a maximum dose of 15 mL. Dose can be doubled for severely immunocompromised
Measles Vaccine (MMR)	Appropriate for any child without 2 previous measles vaccine doses, if given within three days of exposure.	Appropriate for any adult without 2 previous measles vaccine doses (1 dose if born before 1957), if given within three days of exposure.

(OVER)

Proof of measles immunity is determined by meeting one of the following criteria: 1. Documentation of having received two doses of live virus measles vaccine, the first dose on or after 12 months of age and the second dose at least 30 days after the first (the recommended interval between doses is 90 days)					
 □ 2. Serological evidence of measles antibodies. □ 3. Diagnosis of having had measles disease as documented by a physician. 					
	OTHER MEASU	ES SYNDROMES			
OTHER MEASLES SYNDROMES Atypical measles and modified measles are two syndromes frequently misinterpreted in measles surveillance and investigation. These terms should not be generalized or attributed to a rash/febrile illness not consistent with meeting the CDC case definition for measles. By definition:					
☐ Atypical measles syndrome (centripetal rash, lymphadenopathy) occurs only in persons who are exposed to natural measles after they received killed measles vaccine (KMV). (600,000-900,000 persons received KMV in the U.S. from 1963-1967)					
☐ <i>Modified (mild) measles</i> syndrome occurs primarily in patients who received immune globulin (IG) as post-exposure prophylaxis and in young infants who may have some residual maternal antibody.					
	MEASLES CASE	INVESTIGATION			
Measles is a reportable disease. Both clinically confirmed and probable cases must be reported to DHS on a Measles Case Report form, DHS #8345.					
 Investigation process: 1. Upon notification of a measles suspect, complete a □ Measles Case Report Form by conducting an interview with the measles case to: 					
	nformation (<u>at a minimum</u> : name, a	age, address and type of	setting exposed)		
	signs and symptoms (at a minimun				
	ent medical information (recent med		rmation, hospitalization, etc.)		
	t's immune status (history of measl				
	ssible source of exposure (within tw				
☐ travel or	with a person who is suspected of ha	aving measies or who r	ias a Tebrile/rash illness		
□ medical					
	contacts and determine those who	do not have measles im	munity.		
	acts (include persons sharing the sar				
	and not masked); determine those w				
	on of the clinical diagnosis as possib				
	oon as possible, but no longer than 2	24 hours after diagnosis	, by contacting your		
	anch Field representative. line depicts the clinical course of m	easles and may be usefu	il in the investigation process:		
weeks: -3	ncubation Period (7-10 days)	Rash (5-6 days) RASH ONSET	Communicability 1		
WEEKS3	Onset of rash minus 4 days	DATE:	'		
nset of rash minus 14	is probable start of infectious period DATE:	27.1.2.	Onset of rash plus 4 days is probable		
ays is probable xposure	PRODROME: (2-4 days		end of infectious period		
ATE:	cough), coryza, conjunctivitis, Koplik's		DATE:		
	spots				
	MEASLES OUTBREAK CON	ITROL RECOMMEND	DATIONS		
Live measles vaccin	e may prevent disease if administer				
	ify disease and provide temporary p		n six days of exposure.		
(see Recommended Treatment and Prophylaxis Guidelines)					
The following course of action is recommended to prevent the spread of measles disease: 1. Determine the type of acting involved (i.e. school institution comp. haspital EP, clinic or dectarly					
1. Determine the type of setting involved (i.e., school, institution, camp, hospital, ER, clinic, or doctor's office).					
2. Refer to the corresponding DHS Immunization Program Measles Outbreak Investigation and Control (03/91)					
and follow the recommended guidelines for suspect or confirmed measles case.					
3. Identify individuals who <i>do not have measles immunity</i> and follow the recommended prophylactic treatment:					
☐ individuals 12 months of age or older should receive one dose of MMR.					

☐ individuals 0-12 months of age should be referred to their pediatrician for recommended treatment with IG.
☐ individuals who are pregnant should be referred to their OB/GYN for recommended treatment with IG.
4. Report all suspect and confirmed cases to DHS Immunization Branch Field representative.

☐ individuals 6-12 months of age should receive one dose of single antigen measles vaccine or MMR.